Home Telerehabilitation for Arm Recovery After Stroke

Trial details

Who runs it

University of California, Los Angeles

Trial code

NCT06682429

Record updated

5 November 2026

Original description

The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.Read full original descriptionShow less

Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial

The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.

Patients with arm weakness due to stroke that happened in the past 90-270 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.

Inclusion: Age 18-85 years at the time of randomization; The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 90-270 days prior to randomization; The stroke caused upper extremity deficits as defined by Action Research Arm Test score 14-44 (out of 57) at Baseline Visit 1; Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1; Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1; Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent).

Exclusion: Unable or unwilling to perform study procedures/therapy, or expectation of noncompliance with study procedures/therapy, or expectation that subject cannot participate in all study visits; Modified Rankin Scale score was >2 prior to the index stroke; A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke; Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit; Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study; Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site [this can be waived at the discretion of the site PI]; A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures; A diagnosis (apart from the index stroke) that substantially affects paretic arm function; Significant cognitive impairment, defined as Montreal Cognitive Assessment score <22 [a lower score is permitted if due to aphasia and allowed by the site PI]; On isolation precautions, e.g., due to active COVID-19; Severe depression, defined as Geriatric Depression Scale Score >10/15 at Baseline Visit 1; Deficits in communication that interfere with reasonable study participation; Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis; Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye; Life expectancy < 9 months; Pregnant; women of child-bearing potential must have a negative pregnancy test; Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions; Contraindication to MRI.

ClinicalTrials.gov NCT06682429